drugset

drugset / Trial / NCT06836557

Open Label Safety Study of Tradipitant in Idiopathic and Diabetic Gastroparesis

NCT06836557 ↗

Phase 3 Recruiting 100 enrolled Vanda Pharmaceuticals

NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open label, 3-month safety study with tradipitant in patients with idiopathic and diabetic gastroparesis.

Timeline

Start: 2024-01-09
Primary completion: 2025-12
Completion: 2025-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tradipitant	Small molecule	—	Oral

Indications